All In Biotech

Drug Trial Radar · NCT01061177

Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase

A Phase IIIb, Multicentre, Open-label Study of Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome and/or BCR-ABL Positive CML in Chronic Phase

Last checked: Nov 19, 2026Latest source record: Feb 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,090

Actual

Start

May 2010

Primary completion

Jul 2014

Study completion Jul 2014

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 2, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy and safety of nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive/BCR-ABL positive chronic myeloid leukaemia in chronic phase. The aim of the study is to confirm the rates of complete molecular remission (CMR) of nilotinib in newly diagnosed CML chronic phase patients in a pan-European population using the EUTOS standardized laboratories.

Conditions

  • CML in Chronic Phase

Interventions

  • NilotinibDrug

    Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib was dosed on a flat scale and not dosed by body weight. This form of supply was continued for all participants entered into the core study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Molecular Response (MR4^0) at 18 MonthsTime frame: at 18 months

Locations

320 sites in 26 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Innsbruck, Austria

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Rankweil, Austria

  • Novartis Investigative Site

    Salzburg, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Wels, Austria, Austria

  • Novartis Investigative Site

    Bruges, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Charleroi, Belgium

  • Novartis Investigative Site

    Edegem, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Hasselt, Belgium

  • Novartis Investigative Site

    Laken, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Roeselare, Belgium

  • Novartis Investigative Site

    Verviers, Belgium

  • Novartis Investigative Site

    Yvoir, Belgium

  • Novartis Investigative Site

    Aalst, Belgium, Belgium

  • Novartis Investigative Site

    Luxembourg, Luxembourg, Belgium

  • Novartis Investigative Site

    Plovdiv, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Varna, Bulgaria

  • Novartis Investigative Site

    Pleven, Bulgaria, Bulgaria

  • Novartis Investigative Site

    Rijeka, Croatia

  • Novartis Investigative Site

    Zagreb, Croatia

  • Novartis Investigative Site

    Olomouc, CZE, Czechia

  • Novartis Investigative Site

    Brno-Bohunice, Czech Republic, Czechia

  • Novartis Investigative Site

    Hradec Králové, Czech Republic, Czechia

  • Novartis Investigative Site

    Prague, Czech Republic, Czechia

  • Novartis Investigative Site

    Aarhus C, Denmark

  • Novartis Investigative Site

    Copenhagen, Denmark

  • Novartis Investigative Site

    Odense C, Denmark

  • Novartis Investigative Site

    Tartu, Estonia

  • Novartis Investigative Site

    HUS Helsinki, Finland

Showing 40 of 320 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.